Сравнение
LL-37 vs. Semax
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
597562-32-8
80714-61-0
Молекулярная масса
4493.33 g/mol
813.92 g/mol
Период полувыведения
нет данных
0.3 h
Последовательность
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMet-Glu-His-Phe-Pro-Gly-ProМеханизм действия
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Доказательная база
Наивысшая доказательность
Исследование на людях
Исследование на людях
Исследования
4
4
из них на людях
1
2
Зафиксированные эффекты
4
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
0
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between LL-37 and Semax?
- LL-37 is classified as "Исследования (прочее)", while Semax is classified as "Исследования (прочее)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Semax?
- The highest available evidence level is "Исследование на людях" for LL-37 and "Исследование на людях" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Semax in Germany and the United States?
- Германия: LL-37 — Только для исследований, Semax — Не одобрено. США: LL-37 — Только для исследований, Semax — Не одобрено. These are factual summaries with source and review date on the individual pages.